On June 22, 2026, Chairman and Director Mr. Choo Chee Kong offered to acquire between 100,000 and 200,000 company shares from independent shareholders via private purchase agreements. Additionally, Mr. Choo, through EP Capital Inc., invested S$300,000 (approximately US$250,000) into LongevityBank Pte Ltd, a company subsidiary. This investment increased EP Capital Inc.'s stake in LongevityBank from 6.4% to 12.0% based on a S$5 million post-money valuation. Funds will be used to establish an R&D laboratory for product innovation and process improvement. CytoMed Therapeutics operates in the biotechnology industry, focusing on cord blood banking and the development of cord blood-derived therapeutics.